Wird geladen...
Ten Years of Vildagliptin
After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endo...
Gespeichert in:
| Veröffentlicht in: | Eur Endocrinol |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Touch Medical Media
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813464/ https://ncbi.nlm.nih.gov/pubmed/29632607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.54 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|